CN117136068A - 治疗或预防出血性中风后不良继发性神经学后果的方法 - Google Patents

治疗或预防出血性中风后不良继发性神经学后果的方法 Download PDF

Info

Publication number
CN117136068A
CN117136068A CN202280012205.4A CN202280012205A CN117136068A CN 117136068 A CN117136068 A CN 117136068A CN 202280012205 A CN202280012205 A CN 202280012205A CN 117136068 A CN117136068 A CN 117136068A
Authority
CN
China
Prior art keywords
csf
subject
cell
free
therapeutically effective
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280012205.4A
Other languages
English (en)
Chinese (zh)
Inventor
K·阿克雷特
T·金蒂纳塔
R·布兹
M·霍格尔舒费尔
D·谢尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zurich Universitaet Institut fuer Medizinische Virologie
CSL Behring AG
Original Assignee
Zurich Universitaet Institut fuer Medizinische Virologie
CSL Behring AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zurich Universitaet Institut fuer Medizinische Virologie, CSL Behring AG filed Critical Zurich Universitaet Institut fuer Medizinische Virologie
Publication of CN117136068A publication Critical patent/CN117136068A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1722—Plasma globulins, lactoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/72—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
    • G01N33/721—Haemoglobin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
CN202280012205.4A 2021-02-01 2022-01-31 治疗或预防出血性中风后不良继发性神经学后果的方法 Pending CN117136068A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163144043P 2021-02-01 2021-02-01
US63/144,043 2021-02-01
PCT/EP2022/052203 WO2022162218A1 (en) 2021-02-01 2022-01-31 Method of treating or preventing an adverse secondary neurological outcome following a haemorrhagic stroke

Publications (1)

Publication Number Publication Date
CN117136068A true CN117136068A (zh) 2023-11-28

Family

ID=80739092

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280012205.4A Pending CN117136068A (zh) 2021-02-01 2022-01-31 治疗或预防出血性中风后不良继发性神经学后果的方法

Country Status (9)

Country Link
US (1) US20250339492A1 (https=)
EP (1) EP4284407A1 (https=)
JP (1) JP2024504822A (https=)
KR (1) KR20230142569A (https=)
CN (1) CN117136068A (https=)
AU (1) AU2022214388A1 (https=)
CA (1) CA3206884A1 (https=)
IL (1) IL304515A (https=)
WO (1) WO2022162218A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025168750A1 (en) 2024-02-09 2025-08-14 Csl Behring Ag Haptoglobin for use in treating traumatic brain injury (tbi)

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4137307A (en) 1973-11-15 1979-01-30 The Green Cross Corporation Process for preparing haptoglobin aqueous solution using strong anion exchanger
US4061735A (en) 1973-11-15 1977-12-06 The Green Cross Corporation Haptoglobin in aqueous solution and process for preparing the same
DE69534265T2 (de) 1994-12-12 2006-05-04 Beth Israel Deaconess Medical Center, Inc., Boston Chimäre zytokine und ihre verwendung
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US6887470B1 (en) 1999-09-10 2005-05-03 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
AU2003210806A1 (en) 2002-03-05 2003-09-22 Eli Lilly And Company Heterologous g-csf fusion proteins
PL2298347T3 (pl) 2003-05-06 2016-03-31 Bioverativ Therapeutics Inc Białka chimeryczne czynnika krzepnięcia do leczenia zaburzenia hemostazy
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
DK1641823T3 (da) 2003-06-12 2011-12-12 Lilly Co Eli GLP-1-analog fusionsproteiner
RU2370276C2 (ru) 2003-12-31 2009-10-20 Мерк Патент Гмбх Fc-ЭРИТРОПОЭТИН СЛИТЫЙ БЕЛОК С УЛУЧШЕННОЙ ФАРМАКОКИНЕТИКОЙ
US7670595B2 (en) 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
US20060057065A1 (en) 2004-09-11 2006-03-16 Yanming Wang Composition and method to prevent and treat brain and spinal cord injuries
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
WO2013120939A1 (en) 2012-02-15 2013-08-22 Csl Behring Gmbh Von willebrand factor variants having improved factor viii binding affinity
US9534029B2 (en) 2012-10-03 2017-01-03 Csl Behring Ag Method of purifying proteins
JP6370792B2 (ja) 2012-10-03 2018-08-08 ツェー・エス・エル・ベーリング・アクチエンゲゼルシャフト タンパク質の精製方法
IL272167B2 (en) 2017-08-08 2024-02-01 Csl Behring Ag Hemopexin formulations
KR20220009984A (ko) * 2019-05-17 2022-01-25 유니베르시태트 취리히 출혈성 뇌졸중 후 2차 신경학적 이상 반응을 치료하는데 사용하기 위한 합토글로빈

Also Published As

Publication number Publication date
US20250339492A1 (en) 2025-11-06
CA3206884A1 (en) 2022-08-04
AU2022214388A1 (en) 2023-07-27
EP4284407A1 (en) 2023-12-06
IL304515A (en) 2023-09-01
WO2022162218A1 (en) 2022-08-04
JP2024504822A (ja) 2024-02-01
AU2022214388A9 (en) 2024-07-11
KR20230142569A (ko) 2023-10-11

Similar Documents

Publication Publication Date Title
JP2025090742A (ja) 治療用組換えクロトータンパク質ならびにそれを含む組成物および方法
Tayade et al. Functions of alpha 2 macroglobulins in pregnancy
US20190169593A1 (en) Products and methods for assessing and increasing klotho protein levels
Wang et al. Supplementation of ketoacids contributes to the up-regulation of the Wnt7a/Akt/p70S6K pathway and the down-regulation of apoptotic and ubiquitin–proteasome systems in the muscle of 5/6 nephrectomised rats
AU2016277631A1 (en) Polymeric forms of H-NOX proteins
EP2707055B1 (en) Reducing soluble urokinase receptor in the circulation
EA031877B1 (ru) Применение альфа-1-микроглобулина для профилактики или лечения преэклампсии
HUE030274T2 (en) The therapeutic use of the root binding and antioxidant alpha-1 microglobulin
US20240197761A1 (en) Fucosylation and immune modulation in cancer
JP2013529907A (ja) Ｎｇａｌタンパク質変異体及びその使用
US20220211808A1 (en) Haptoglobin for use in treating an adverse secondary neurological outcome following a haemorrhagic stroke
CN108463729B (zh) 以adamts13作为主要成分的诊断药和药品
CN117136068A (zh) 治疗或预防出血性中风后不良继发性神经学后果的方法
EA049722B1 (ru) Способ лечения или профилактики неблагоприятного вторичного неврологического исхода вследствие геморрагического инсульта
Ohtsuki et al. Is P‐glycoprotein Involved in Amyloid‐β Elimination Across the Blood–Brain Barrier in Alzheimer's Disease?
RU2818474C2 (ru) Гаптоглобин для применения в лечении неблагоприятного вторичного неврологического исхода после геморрагического инсульта
TW202423961A (zh) 投予軟組織之凝血因子ⅸ變異體多肽
AU2005211556A1 (en) Method Of Modulation
US20210322508A1 (en) Peptides and compositions for targeted treatment and imaging
WO2008097563A1 (en) Methods for maintaining blood-brain barrier integrity in hypertensive subjects using a delta-pkc inhibitor
CN114206377A (zh) 重组adamts13治疗镰状细胞病的应用
JP7515557B2 (ja) 凝固異常を伴う敗血症の治療及び／又は改善のための医薬
US20250304655A1 (en) Expression System for Producing a Recombinant Haptoglobin (Hp) Beta Chain
US20240392280A1 (en) Products and methods for assessing and increasing klotho protein levels
JP2013527125A (ja) 心臓ステント移植を受ける患者を治療する方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination